<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14929">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02912520</url>
  </required_header>
  <id_info>
    <org_study_id>ORV001</org_study_id>
    <nct_id>NCT02912520</nct_id>
  </id_info>
  <brief_title>Comparison of IgA Levels in the Bronchoalveolar Lavage Fluid of Patients With and Without Antibiotic Therapy</brief_title>
  <official_title>Comparison of IgA Levels in the Bronchoalveolar Lavage Fluid of Patients With and Without Antibiotic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators hypothesize that Immunoglobine (Ig) production is influenced by the microbiota
      of the gut. Investigators will compare microbiota-dependent Ig production in the
      bronchoalveolar lavage fluid of patients with and without antibiotic therapy in order to
      detect significant differences.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IgA levels in the bronchoalveolar lavage fluid</measure>
    <time_frame>2 weeks of ICU stay</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of detected bacterial, viral, and fungal infections per patient</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Immunoglobulin A</condition>
  <arm_group>
    <arm_group_label>Patients with antibiotic therapy</arm_group_label>
    <description>Patients with antibiotic therapy for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without antibiotic therapy</arm_group_label>
    <description>Patients without any antibiotic therapy in the last 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Bacterial Agents</intervention_name>
    <description>administration of any antibiotic substance(s) over the course of 2 weeks</description>
    <arm_group_label>Patients with antibiotic therapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bronchoalveolar lavage fluid of patients with and without antibiotic therapy.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive inclusion of eligible patients admitted to the ICU.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  endotracheal intubation

          -  antibiotic therapy for 2 weeks OR no antibiotic therapy

        Exclusion Criteria:

          -  pregnancy

          -  immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Robak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver Robak, MD</last_name>
    <phone>+4314040044560</phone>
    <email>oliver.robak@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Robak, MD</last_name>
      <phone>+436648248878</phone>
      <email>oliver.robak@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Hoogkamp-Korstanje JA, de Koning J, Heesemann J, Festen JJ, Houtman PM, van Oyen PL. Influence of antibiotics on IgA and IgG response and persistence of Yersinia enterocolitica in patients with Yersinia-associated spondylarthropathy. Infection. 1992 Mar-Apr;20(2):53-7.</citation>
    <PMID>1582684</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 20, 2016</lastchanged_date>
  <firstreceived_date>September 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Oliver Robak</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
